Impact of the European Clinical Trials Directive on prospective academic clinical trials associated with BMT

10Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The European Clinical Trials Directive (EU 2001; 2001/20/EC) was introduced to improve the efficiency of commercial and academic clinical trials. Concerns have been raised by interested organizations and institutions regarding the potential for negative impact of the Directive on non-commercial European clinical research. Interested researchers within the European Group for Blood and Marrow Transplantation (EBMT) were surveyed to determine whether researcher experiences confirmed this view. Following a pilot study, an internet-based questionnaire was distributed to individuals in key research positions in the European haemopoietic SCT community. Seventy-one usable questionnaires were returned from participants in different EU member states. The results indicate that the perceived impact of the European Clinical Trials Directive has been negative, at least in the research areas of interest to the EBMT. © 2011 Macmillan Publishers Limited All rights reserved.

Cite

CITATION STYLE

APA

Frewer, L. J., Coles, D., Van Der Lans, I. A., Schroeder, D., Champion, K., & Apperley, J. F. (2011). Impact of the European Clinical Trials Directive on prospective academic clinical trials associated with BMT. Bone Marrow Transplantation, 46(3), 443–447. https://doi.org/10.1038/bmt.2010.139

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free